Suggested remit: To appraise the clinical and cost effectiveness of tirzepatide within its marketing authorisation for managing obesity or overweight with risk factors.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6179
|
Provisional Schedule
| Expected publication |
23 December 2024 |
Project Team
| Project lead |
Jennifer Upton |
Email enquiries
| External Assessment Group |
Warwick Evidence, Warwick Medical School, University of Warwick |
Stakeholders
| Companies sponsors |
Eli Lilly and Company |
| Others |
Department of Health and Social Care |
| |
Health Technology Wales (HTW) |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
All About Obesity |
| |
Diabetes UK |
| |
Obesity UK |
| Professional groups |
Association for the Study of Obesity |
| |
British Obesity and Metabolic Surgery Society |
| |
Royal College of General Practitioners |
| |
Royal College of Physicians |
| Comparator companies |
NovoNordisk |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
BNF |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
MHRA |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
|
Date
|
Update
|
|
05 December 2024 - 19 December 2024
|
Final draft guidance: 1 |
|
03 October 2024
|
Statement |
|
03 October 2024
|
The following statement and documents have been added to the project documents section of the webpage:
Following the Technology Appraisal Committee meeting on 13 August 2024, we are consulting with consultees and commentators on the case for extending the statutory 3-month period for funding of tirzepatide for managing overweight and obesity.
Following the consultation, NICE Guidance Executive will make a final decision on whether the statutory period of funding should be extended. The final decision will be included in the Final Draft Guidance which will be issued for appeal with publication of final guidance on this appraisal anticipated in December 2024 if no appeals are received.
The request from NHS England to vary the funding requirement timeframe for implementation of the NICE committee’s final draft recommendation is included here for information.
The committee’s final recommendation on tirzepatide for managing overweight and obesity is as follows:
Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity, in adults, only if they have:
• an initial body mass index (BMI) of at least 35 kg/m2 and
• at least 1 weight-related comorbidity.
Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.
If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, decide whether to continue treatment, taking into account the benefits and risks of treatment for the person.
|
|
13 August 2024
|
Committee meeting: 3 |
|
13 August 2024
|
Declaration of interests |
|
13 August 2024
|
Declaration of interests |
|
04 June 2024 - 25 June 2024
|
Draft guidance |
|
09 April 2024
|
Committee meeting: 2 |
|
06 March 2024
|
The next appraisal committee meeting will now take place on 9 April 2024. |
|
08 February 2024
|
The appraisal was discussed by the technology appraisal committee on 16 January 2024. The committee requires further information before it can make a recommendation on tirzepatide for obesity. We have requested this information from stakeholders and the committee will reconsider this topic at its meeting on 12 March 2024. |
|
16 January 2024
|
Committee meeting: 1 |
|
13 June 2023
|
Invitation to participate |
|
26 May 2023
|
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
|
23 March 2023
|
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Tirzepatide for managing overweight and obesity have been revised. It is anticipated that the appraisal will begin in mid-May 2023 when we will write to you about how you can get involved. |
|
24 January 2023 - 21 February 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
24 January 2023
|
In progress. Scoping commenced |
|
17 October 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual